Keymed Biosciences, Inc. (2162) AI Stock Analysis

• Market Cap: HK$16.44B
• Dividend Yield: N/A
• Average Volume (3M): 1.75M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: 964.40%
• EPS Growth: 65.90%
• Country: HK
• Employees: 1,258
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 298,735,570
• 10 Day Avg. Volume: 1,976,819
• 30 Day Avg. Volume: 1,752,076
• PEG Ratio: -0.34
• Price to Book (P/B): 3.07
• Price to Sales (P/S): 17.76
• P/FCF Ratio: -7.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$85.48
• Price Target Upside: 36.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -2.15
• Revenue Forecast (FY): HK$857.71M

• Rating: 41 Neutral
• Price Target: HK$59.00 ▼(-6.05% Downside)

Keymed Biosciences, Inc. faces significant challenges with ongoing losses and negative cash flows despite revenue growth. The technical indicators suggest bearish momentum, and the valuation is unattractive due to a negative P/E ratio. The company's strong balance sheet is a positive aspect, but the path to profitability remains uncertain.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong demand for Keymed's products, suggesting successful market penetration and potential for future profitability as the company scales its operations.

Strong Balance Sheet

A strong balance sheet with low leverage provides financial stability and flexibility, enabling Keymed to invest in R&D and strategic initiatives without the pressure of high debt obligations.

High Gross Profit Margin

A high gross profit margin reflects efficient production and pricing strategies, which can support long-term profitability as operational efficiencies improve and economies of scale are realized.

Negative Factors

Operating Losses

Ongoing operating losses highlight challenges in achieving profitability, which could impact long-term sustainability if costs are not managed effectively or revenue growth does not accelerate.

Negative Cash Flow

Negative cash flow indicates that Keymed is not yet able to convert its revenue into cash, which is critical for funding operations and growth without relying on external financing.

Negative ROE

A negative ROE suggests that the company is not generating sufficient returns on equity, which may deter investors and affect the company's ability to raise capital for future growth initiatives.

Keymed Biosciences, Inc. Business Overview & Revenue Model

Company Description

Keymed Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapies for autoimmune and inflammatory diseases. The company operates primarily in the biotechnology sector, leveraging advanced research and development to create a pipeline of monoclonal antibody products designed to address unmet medical needs. Keymed's core offerings include novel drug candidates that target specific immune pathways, aiming to provide effective treatment options for patients suffering from chronic conditions.

How the Company Makes Money

Keymed Biosciences, Inc. generates revenue primarily through the development and commercialization of its therapeutic products. The company earns money by entering into strategic partnerships and collaborations with larger pharmaceutical firms, which may include upfront payments, milestone payments based on development progress, and royalties on future sales of the products. Additionally, Keymed may receive funding from governmental and private grants aimed at supporting biotech innovation, as well as revenue from potential licensing agreements for its proprietary technologies. The company's ability to secure these partnerships and funding sources is crucial for sustaining its research initiatives and advancing its product pipeline.

Keymed Biosciences, Inc. Financial Statement Overview

Summary

Keymed Biosciences, Inc. is experiencing revenue growth, but the company is still operating at a loss with negative net profit and EBIT margins. Despite a strong balance sheet with low leverage, negative cash flows and net losses pose risks to financial sustainability.

Income Statement

Keymed Biosciences, Inc. has shown significant revenue growth from 2022 to 2024, with revenue increasing from 100 million to 428 million. However, the company is still operating at a loss, with a negative net profit margin and EBIT margin. The gross profit margin is high, indicating good product profitability, but this is offset by high operating expenses leading to negative net income.

Balance Sheet

The company maintains a strong equity position with a debt-to-equity ratio below 0.5, indicating low leverage. However, the ROE is negative due to consistent net losses. The equity ratio is healthy, suggesting a strong asset base compared to liabilities, which is crucial for future growth and stability.

Cash Flow

The free cash flow remains negative, reflecting high capital expenditures and operating losses. There is an absence of operating cash flow, highlighting challenges in converting revenue into cash. The company has not demonstrated positive cash flow to net income ratios, which are critical for long-term financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	872.19M	428.12M	354.10M	100.06M	110.27M	0.00
Gross Profit	830.25M	415.92M	317.22M	97.48M	93.07M	0.00
EBITDA	-312.61M	-574.46M	-269.77M	-259.25M	-3.86B	-135.09M
Net Income	-257.34M	-515.24M	-359.36M	-308.12M	-3.90B	-832.73M
Balance Sheet
Total Assets	4.63B	3.77B	3.88B	3.93B	3.93B	529.95M
Cash, Cash Equivalents and Short-Term Investments	2.80B	2.16B	2.72B	3.18B	3.52B	354.08M
Total Debt	872.30M	753.24M	418.71M	121.97M	39.26M	66.86M
Total Liabilities	1.44B	1.29B	896.11M	593.10M	289.07M	1.62B
Stockholders Equity	3.19B	2.47B	2.99B	3.34B	3.65B	-1.09B
Cash Flow
Free Cash Flow	-854.73M	-1.00B	-686.23M	-681.48M	-387.50M	-139.26M
Operating Cash Flow	-604.67M	-789.63M	-303.62M	-401.93M	-214.64M	-119.36M
Investing Cash Flow	-92.13M	67.71M	468.20M	-645.59M	-2.04B	-113.07M
Financing Cash Flow	905.48M	283.90M	72.13M	-8.06M	3.64B	7.40M

Keymed Biosciences, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 62.80
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2162, the sentiment is Positive. The current price of 62.8 is above the 20-day moving average (MA) of 55.32, above the 50-day MA of 57.85, and above the 200-day MA of 56.36, indicating a bullish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 58.04 is Neutral, neither overbought nor oversold. The STOCH value of 84.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2162.

Keymed Biosciences, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2315	66 Neutral	HK$14.25B	99.64	16.13%	―	48.38%	―
1672	54 Neutral	HK$12.49B	-44.18	-12.74%	―	-76.58%	-4.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2171	44 Neutral	HK$9.52B	-16.56	-42.46%	―	1219.19%	25.15%
2162	41 Neutral	HK$16.44B	-57.23	-8.79%	―	964.40%	65.90%
2157	40 Underperform	HK$9.91B	-47.34	-21.42%	―	240.05%	-140.09%